Biohaven's clinical development program for troriluzole has spanned over eight years, including long-term safety data and the first large-scale, multi-center registrational trials in SCA.

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Based on FDA Priority Review timelines and, if ultimately approved, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025. The Company had previously achieved positive ...

Biohaven’s lead clinical asset ... topline results from its pivotal Phase 3 study which demonstrated that Troriluzole dosed at 200mg daily slowed disease progression of 50-70%, which the ...

Biohaven reported Q4 earnings on March 3 and ... the primary focus for the stock to remain on upcoming FDA action on Troriluzole for Spinocerebellar Ataxia this summer. Effectively assess a ...

Troriluzole 200 mg dosed orally ... BHV-1300 and BHV-1310 are IgG degraders; Biohaven introduced next generation TRAPTM (Targeted Removal of Aberrant Protein) degraders, which are highly selective ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...